New technologies and challenges of novel virus detection

PDA Journal of Pharmaceutical Science and Technology

Volumn 68, Issue 6, 2014, Pages 661-666

  Khan, Arifa S ^a   Ma, Hailun ^a   Taliaferro, Lanyn P ^a   Galvin, Teresa A ^a   Shaheduzzaman, Syed ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Adventitious agents; Cell substrate; Endogenous retroviruses; Latent viruses; Massively parallel sequencing; Novel viruses; Occult viruses; PLEX ID; Virus microarrays

Indexed keywords

CONFERENCE PAPER; MDCK CELL LINE; MICROARRAY ANALYSIS; NONHUMAN; SF9 CELL LINE; TECHNOLOGY; VIRUS DETECTION; VIRUS GENOME; ANIMAL; BIOLOGY; CELL CULTURE TECHNIQUE; DNA MICROARRAY; DOG; DRUG CONTAMINATION; ELECTROSPRAY MASS SPECTROMETRY; GENETIC DATABASE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; PHARMACEUTICS; POLYMERASE CHAIN REACTION; PREVENTION AND CONTROL; PROCEDURES; VIROLOGY; VIRUS;

BIOLOGICAL PRODUCT; VIRUS DNA; VIRUS RNA;

ANIMALS; BIOLOGICAL PRODUCTS; BIOPHARMACEUTICS; CELL CULTURE TECHNIQUES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DNA, VIRAL; DOGS; DRUG CONTAMINATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RNA, VIRAL; SF9 CELLS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VIROLOGY; VIRUSES;

EID: 84915793494     PISSN: 10797440     EISSN: 19482124     Source Type: Journal    
DOI: 10.5731/pdajpst.2014.01029     Document Type: Conference Paper

References (21)

1. Khan, A. S. Testing considerations for novel cell substrates: a regulatory perspective. PDA J. Pharm. Sci. Technol. 2010, 64 (5), 426-431.
2. Khan, A. S. Current testing methods and challenges for detection of adventitious viruses. PDA J. Pharm. Sci. Technol. 2011, 65 (6), 627-633.
3. http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm288695.htm.
4. CBER. Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. U.S. FDA: Rockville, MD, February 2010.
5. Khan, A. S.; Ma, W.; Ma, Y. K.; Kumar, A.; Williams, D. K.; Muler, J.; Ma, H.; Galvin, T.A. Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction. Biologicals 2009, 37 (3), 196-201.
6. Ma, H.; Ma, Y. K.; Ma, W.; Williams, D. K.; Galvin, T. A.; Khan, A. S. Chemical induction of endogenous retrovirus particles from the Vero cell line of African green monkeys. J. Virol. 2011, 85 (13), 6579-6588.
7. Ma, W.; Galvin, T. A.; Ma, H.; Ma, Y. K.; Muller, J.; Khan, A. S. Optimization of chemical induction conditions for human herpesvirus 8 (HHV-8) reactivation with 12-O-tetradecanoyl-phorbor-13-acetate (TPA) from latently-infected BC-3 cells. Biologicals 2011, 39 (3), 158-166.
8. Khan, A. S.; Lubiniecki, A.; and King, K. Conference Report: PDA/FDA Adventitious agents and novel cell substrates: Emerging technologies and new challenges, Nov. 3-4 2011, Rockville, MD. PDA J. Pharm. Sci. Technol. 2012, 66 (6), 502-511.
9. Robertson, J. S.; Nicolson, C.; Riley, A. M.; Bentley, M.; Dunn, G.; Corcoran, T.; Schild, G. C.; Minor, P. Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines. Biologicals 1997, 25 (4), 403-414.
10. Khan, A. S.; Maudru, T.; Thompson, A.; Muller, J.; Sears, J. F.; Peden, K. W. The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus. J. Clin. Virol. 1998, 11 (1), 7-18.
11. Tsang, S. X.; Switzer, W. M.; Shanmugam, V.; Johnson, J. A.; Goldsmith, C.; Wright, A.; Fadly, A.; Thea, D.; Jaffe, H.; Folks, T. M.; Heneine, W. Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps vaccines derived from chicken cells: investigation of transmission to vaccine recipients. J. Virol. 1999, 73 (7), 5843-5851.
12. Lovatt, A.; Black, J.; Galbraith, D.; Doherty, I.; Moran, M. W.; Shepherd, A. J.; Griffen, A.; Bailey, A.; Wilson, N.; Smith, K. T. High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J. Virol Methods 1999, 82 (2), 185-200.
13. Cox, M. M.; Hollister, J. R. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009, 37 (3), 182-189.
14. Liu, J.; Mani, S.; Schwartz, R.; Richman, L.; Tabor, D. E. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine. 2010, 28 (5), 1285-1293.
15. Omeir, R. L.; Teferedegne, B.; Foseh, G. S.; Beren, J. J.; Snoy, P. J.; Brinster, L. R.; Cook, J. L.; Peden, K.; Lewis, Jr., A. M. Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells. Comp. Med. 2011, 61 (3), 243-250.
16. Onions, D.; Egan, W.; Jarrett, R.; Novicki, D.; Gregersen, J. P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals. 2010, 38 (5), 544-551.
17. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm335836.htm (Flublok).
18. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328629.htm (Flucelvax).
19. Taliaferro, L. P.; Galvin, T. A.; Ma, H.; Shaheduzzaman, S.; Williams, D. K.; Glasner, D. R.; Khan, A. S. Evaluation of the broad-range PCR-electrospray ionization mass spectrometry (PCR/ESI-MS) system and virus microarrays for virus detection. Viruses 2014, 6 (5), 1876-1896.
20. Ma, H.; Galvin, T. A.; Glasner, D. R.; Shaheduzzaman, S.; Khan, A. S. Identification of a novel rhabdovirus in Spodoptera frugiperda cell lines. J. Virol. 2014, 88 (12), 6576-6585.
21. Duncan, P. Summary of the Advanced Virus Detection Technologies Users Group efforts - 2013. PDA J. Pharm. Sci. Technol. 2014, (this issue).